Comparative Pharmacology
Head-to-head clinical analysis: QOLIANA versus TYLENOL W CODEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QOLIANA versus TYLENOL W CODEINE.
QOLIANA vs TYLENOL W/ CODEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
Codeine is a prodrug that is metabolized to morphine, which acts as a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
1-2 tablets (300-600 mg acetaminophen / 30-60 mg codeine) every 4-6 hours as needed; maximum 12 tablets/day (codeine max 360 mg, acetaminophen max 3600 mg). Route: oral.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Codeine: 2.5-4 hours (slower in CYP2D6 poor metabolizers).
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Renal: ~90% as glucuronide conjugates (acetaminophen 50-70%, codeine 10-15%), 10-15% as free acetaminophen, <5% free codeine; biliary/fecal: <5%.
Category C
Category D/X
Opioid Agonist
Opioid Agonist